Park, Yeon Hee

Pembrolizumab for Early Triple-Negative Breast Cancer

Schmid, P., Cortes, J., Pusztai, L., McArthur, H., Kümmel, S., Bergh, J., Denkert, C., Park, Y. H., Hui, R., Harbeck, N., et al. (2020) · New England Journal of Medicine

Breast Cancer Treatment StudiesCancer Immunotherapy and Biomarkers

Cited by 3,270

Trastuzumab deruxtecan in previously treated HER2-positive breast cancer

Modi, S., Saura, C., Yamashita, T., Park, Y. H., Kim, S.-B., Tamura, K., Andre, F., Iwata, H., Ito, Y., Tsurutani, J., et al. (2020) · New England Journal of Medicine

HER2/EGFR in Cancer ResearchLung Cancer Treatments and Mutations

Cited by 2,006

Single-cell RNA-seq enables comprehensive tumour and immune cell profiling in primary breast cancer

Chung, W., Eum, H. H., Lee, H.-O., Lee, K.-M., Lee, H.-B., Kim, K.-T., Ryu, H. S., Kim, S., Lee, J. E., Park, Y. H., et al. (2017) · Nature Communications

Single-cell and spatial transcriptomicsCancer Genomics and Diagnostics

Cited by 992

Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer

Turner, N. C., Oliveira, M., Howell, S. J., Dalenc, F., Cortes, J., Gomez Moreno, H. L., Hu, X., Jhaveri, K., Krivorotko, P., Loibl, S., et al. (2023) · New England Journal of Medicine

Advanced Breast Cancer TherapiesPI3K/AKT/mTOR signaling in cancer

Cited by 813

Alpelisib (ALP) + fulvestrant (FUL) in patients (pts) with PIK3CA-mutated (mut) hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDKi) + aromatase inhibitor (AI): BYLieve study results.

Rugo, H. S., Lerebours, F., Ciruelos, E., Drullinsky, P., Ruiz Borrego, M., Neven, P., Park, Y. H., Prat, A., Bachelot, T., Juric, D., et al. (2020) · Journal of Clinical Oncology

Advanced Breast Cancer TherapiesPI3K/AKT/mTOR signaling in cancer

Cited by 56